SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.260-5.8%9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: luckydog887/25/2025 6:20:21 AM
1 Recommendation

Recommended By
erippetoe

  Read Replies (1) of 1222
 
Both hitting the wires this morning:

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246%
Unit Growth Since J-Code with Regulatory Updates

(06:20 AM EDT, 07/25/2025 (MT Newswires) -- ImmunityBio (IBRX) reported Q2 preliminary revenue Friday of $26.4 million. Analysts polled by FactSet expected $21.5 million.)

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

finance.yahoo.com

finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News